The goal of this proposal is to study the newly identified inhibitor of the Raf-l kinase designated RKJP. Raf-l is a cytoplasmic serine/threonine kinase whose activity plays a pivotal role in the control of the mitogen-activated protein kinase pathway (MAPK). Raf-1 kinase activity is tightly regulated by an interplay of positive and negative regulators. RKIP is a negative regulator of Raf-l and MAPK pathway signaling that was recently identified in a collaborative effort between my lab and the labs of Walter Kolch and David Rose. In this proposal I outline experiments to investigate two aspects of RKJP function.
In Aim One I will investigate in detail the mechanism by which RKJP contributes to the regulation of the MAPK pathway. Specifically, I will investigate the role of phosphorylation in the regulation of the Raf-RKTP interaction. Several lines of evidence indicate that RKJP binds to phosphorylated residues on proteins. I will thus investigate whether the phosphorylation status of Raf- 1 plays a role in regulating the RKIP-Raf- 1 interaction. The second set of experiments is based on the observation that RKIP is a phosphoprotein in vivo and a substrate of several kinases in vitro. Sites of in vitro phosphorylation will be mapped. In vivo phosphorylation sites will be determined using a combination of mass spectrometry and metabolic labeling followed by peptide mapping and sequencing. Once in vivo sites are ascertained, phosphopeptide-specific antibodies will be raised. The in vivo phosphorylation status of RKIP will be examined under a variety of physiological conditions known to stimulate MAPK activity.
In Aim Two I will investigate the role of RKIP in the NF-KB signaling cascade. I have obtained experimental evidence that modulation of RKIP expression levels affects NF-kB activation, and I have shown that RKIP physically interacts with two components of the NF-kB cascade, NIK and TAK 1. I will employ a combination of genetic and biochemical methods to study the effects of RKIP on NF-kB signaling. The primary goal of this line of investigation will be to define the targets of RKIP in the NF-kB signaling pathway, and to initiate studies into how they are regulated. In summary, I believe that the experiments in this proposal will provide a new handle for understanding Raf- 1 signaling, and will initiate studies to expose the full spectrum of RKIP functions.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM064767-06
Application #
6861829
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Ikeda, Richard A
Project Start
2001-08-01
Project End
2006-12-31
Budget Start
2005-04-01
Budget End
2006-12-31
Support Year
6
Fiscal Year
2005
Total Cost
$213,518
Indirect Cost
Name
University of Toledo
Department
Biochemistry
Type
Schools of Medicine
DUNS #
807418939
City
Toledo
State
OH
Country
United States
Zip Code
43614
Tang, Huihui; Park, Sungdae; Sun, Shao-Cong et al. (2010) RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB kinase complex. FEBS Lett 584:662-8
Beach, S; Tang, H; Park, S et al. (2008) Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27:2243-8
Rath, Oliver; Park, Sungdae; Tang, Hui-hui et al. (2008) The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cell Signal 20:935-41
Mc Henry, Kevin T; Montesano, Roberto; Zhu, Shoutian et al. (2008) Raf kinase inhibitor protein positively regulates cell-substratum adhesion while negatively regulating cell-cell adhesion. J Cell Biochem 103:972-85
Park, Sungdae; Rath, Oliver; Beach, Sandy et al. (2006) Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Lett 580:6405-12
Park, Sungdae; Yeung, Miranda L; Beach, Sandy et al. (2005) RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24:3535-40
Chatterjee, Devasis; Bai, Yin; Wang, Zhe et al. (2004) RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515-23
Hindley, Alison D; Park, Sungdae; Wang, Lily et al. (2004) Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N6 position. FEBS Lett 556:26-34
Yeung, K C; Rose, D W; Dhillon, A S et al. (2001) Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21:7207-17